VRTX - Vertex Pharmaceuticals Incorporated
247.78 0.00 (0.00%)
After hours: 4:57PM EST
| Previous close | 245.93 |
| Open | 249.85 |
| Bid | 247.65 x 900 |
| Ask | 254.00 x 1100 |
| Day's range | 245.27 - 249.34 |
| 52-week range | 163.68 - 249.34 |
| Volume | 845,212 |
| Avg. volume | 1,362,116 |
| Market cap | 64.242B |
| Beta (5Y monthly) | 1.45 |
| PE ratio (TTM) | 54.94 |
| EPS (TTM) | 4.51 |
| Earnings date | 27-Apr-2020 - 03-May-2020 |
| Forward dividend & yield | N/A (N/A) |
| Ex-dividend date | N/A |
| 1y target est | 266.60 |
- Investor's Business Daily Video
Vertex Tests Buy Point
Vertex Pharmaceuticals edged lower for a third straight session, dipping intraday below a 225.76 buy point. Looks like it'll close above that 4-weeks tight entry.
- Zacks
What's in Store for Vertex in 2020 After a Remarkable 2019?
In 2020, Vertex's (VRTX) sales are expected to be primarily driven by Trikafta and higher international revenues.
- Zacks
Zacks.com featured highlights include: Chipotle Mexican Grill, Vertex Pharmaceuticals, ResMed, Spirit Airlines and OneMain
Zacks.com featured highlights include: Chipotle Mexican Grill, Vertex Pharmaceuticals, ResMed, Spirit Airlines and OneMain
- Zacks
3 Reasons Growth Investors Will Love Vertex (VRTX)
Vertex (VRTX) possesses solid growth attributes, which could help it handily outperform the market.
- Zacks
Why Vertex (VRTX) Might be Well Poised for a Surge
Vertex (VRTX) shares have started gaining and might continue moving higher in the near term, as indicated by solid earnings estimate revisions.
- Zacks
Is Vertex Pharmaceuticals (VRTX) Stock Outpacing Its Medical Peers This Year?
Is (VRTX) Outperforming Other Medical Stocks This Year?
- Zacks
Biotech Stock Roundup: Earnings Updates From VRTX, AMGN, GILD; AIMT Gains FDA Nod
Many biotech bigwigs came out with their fourth-quarter numbers in the past week.
- Zacks
Vertex (VRTX) Hits 52-Week High, Can the Run Continue?
Vertex (VRTX) is at a 52-week high, but can investors hope for more gains in the future? We take a look at the company's fundamentals for clues.
- Zacks
NASDAQ Reaches New Closing High as Rebound Continues
NASDAQ Reaches New Closing High as Rebound Continues
- Zacks
Buy this Cloud-Based Business Services Stock After Earnings on Strong Growth?
ServiceNow posted stronger-than-projected Q4 2019 results on January 29. Analysts have since raised their fiscal 2020 and 2021 earnings estimates for the fast-growing, cloud-focused business services firm...
- Zacks
Vertex (VRTX) Q4 Earnings Beat on Solid CF Product Sales
Vertex (VRTX) rides high on earnings and revenue beat in Q4. The company provides solid outlook for 2020 resulting in the shares to go up in after-hours trading.
- Zacks
Vertex Pharmaceuticals (VRTX) Q4 Earnings and Revenues Top Estimates
Vertex (VRTX) delivered earnings and revenue surprises of 40.50% and 41.36%, respectively, for the quarter ended December 2019. Do the numbers hold clues to what lies ahead for the stock?
- Business Wire
Vertex Reports Full-Year and Fourth-Quarter 2019 Financial Results
Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today reported consolidated financial results for the full year and fourth quarter ended December 31, 2019 and provided full-year 2020 financial guidance.
- Investing.com
Vertex Earnings, Revenue Beat in Q4
Investing.com - Vertex (NASDAQ:VRTX) reported on Thursday fourth quarter earnings that beat analysts' forecasts and revenue that topped expectations.
- Yahoo Finance
Amazon earnings, Q4 GDP: What to know in markets Thursday
E-commerce giant Amazon’s (AMZN) earnings and U.S. Q4 GDP take centerstage on a busy Thursday.
- Zacks
Big Drug/Biotech Stock Earnings on Jan 30: BIIB, ALXN & More
Let us take a look at five big drug/biotech companies due to release their quarterly results on Jan 30.
- Zacks
Why Vertex (VRTX) Might Surprise This Earnings Season
Vertex (VRTX) is seeing favorable earnings estimate revision activity and has a positive Zacks Earnings ESP heading into earnings.
- Zacks
Can CF Drugs Drive Growth for Vertex (VRTX) in Q4 Earnings?
On Vertex's (VRTX) fourth-quarter earnings call, investor focus will be on the sales uptake of its CF drugs and the unveiling plans for the newly-approved Trikafta triple combination regimen.
- Zacks
Vertex Pharmaceuticals (VRTX) Stock Sinks As Market Gains: What You Should Know
Vertex Pharmaceuticals (VRTX) closed the most recent trading day at $233.91, moving -0.3% from the previous trading session.
- Zacks
Vertex Pharmaceuticals (VRTX) Expected to Beat Earnings Estimates: Should You Buy?
Vertex (VRTX) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
- Zacks
Why Vertex (VRTX) is Poised to Beat Earnings Estimates Again
Vertex (VRTX) has an impressive earnings surprise history and currently possesses the right combination of the two key ingredients for a likely beat in its next quarterly report.
- Business Wire
Vertex to Announce Full-Year and Fourth-Quarter 2019 Financial Results on January 30
Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) will report its full-year and fourth-quarter 2019 financial results on Thursday, January 30, 2020 after the financial markets close. The company will host a conference call and webcast at 4:30 p.m. ET. To access the call, please dial (866) 501-1537 (U.S.) or +1 (720) 545-0001 (International).
